Adlai Nortye Ltd. (NASDAQ:ANL) Sees Large Decrease in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL) was the target of a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 10,400 shares, a decline of 32.9% from the July 31st total of 15,500 shares. Based on an average daily volume of 13,600 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of Adlai Nortye

An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its holdings in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 as of its most recent SEC filing. 35.21% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a report on Thursday, June 20th.

Adlai Nortye Price Performance

Shares of NASDAQ ANL traded up $0.01 during trading on Thursday, hitting $3.00. 2,977 shares of the company were exchanged, compared to its average volume of 9,778. Adlai Nortye has a 1 year low of $2.69 and a 1 year high of $19.30. The firm’s fifty day moving average price is $3.30 and its 200 day moving average price is $7.24.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.